Amneal Taps Strides To Add More Competition To US Vascepa Market

Originator Amarin Claims Continued Market Lead – Three Years After First Generic Launch

Amneal has in-licensed Strides’ generic version of Vascepa to compete with the several ANDA products already on the market.

heart shape of Fish oil, soft capsule, omega, supplement isolated on white background,healthy product concept - Image
• Source: Shutterstock

Amneal says it will begin shipping a US generic version of Amarin’s Vascepa (icosapent ethyl) 500mg and 1g soft gel capsules before the year is out, after in-licensing the purified fish oil product from Indian firm Strides Pharma Science.

Strides described the partnership as “testament to our commitment to excellence and the pursuit of cutting-edge solutions,” while Amneal noted that it remained “on-track to launch over 40 new products in 2023

More from Deals

More from Business